Head-to-head evidence
HS-20137 vs tildrakizumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: IL-23 p19 · full Psoriasis pipeline
HS-20137
Developed by Hansoh Pharmaceutical Group
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: March 2027 · NCT06844799 (registry estimate)
tildrakizumab · Ilumya
Marketed by Sun Pharmaceutical Industries
NCT01729754 · Phase 3 · completed
This was a large, randomized, quadruple-blind, placebo- and active-controlled Phase 3 trial (N=1,090) in moderate-to-severe plaque psoriasis. The primary efficacy endpoints, PASI-75 and PGA clear/minimal at Week 12, were both statistically significant in favor of tildrakizumab 200 mg and 100 mg compared with placebo (p<0.001). The strong design and positive primary results provide high-quality evidence of treatment benefit.
Next expected readout: September 2028 · NCT05390515 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HS-20137's landscape · tildrakizumab's landscape